ziprasidone has been researched along with Psychotic Disorders in 148 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (4.73) | 18.2507 |
| 2000's | 86 (58.11) | 29.6817 |
| 2010's | 51 (34.46) | 24.3611 |
| 2020's | 4 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Andreasson, T; Mattsson, C; Sonesson, C; Waters, N | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J | 1 |
| Correll, CU; DiPetrillo, L; Jiang, Y; Liu, Y; Pathak, S; Todtenkopf, MS | 1 |
| Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J | 1 |
| Alisauskiene, R; Gjestad, R; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM | 1 |
| Ensom, MHH; Johnson, EG; Johnson, HE; Wilby, KJ | 1 |
| Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Crespo-Facorro, B; Díaz Martínez, Á; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suárez Pinilla, P; Vázquez-Bourgon, J | 1 |
| Bateman, BT; Cohen, JM; Cohen, LS; Desai, RJ; Glynn, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Park, Y; Patorno, E | 1 |
| Crespo-Facorro, B; Gómez-Revuelta, M; González-Pinto, A; Juncal-Ruiz, M; Ortiz-García de la Foz, V; Pelayo-Terán, JM; Vázquez-Bourgon, J | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Mata, I; Ortiz-García de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM; Vázquez-Barquero, JL | 1 |
| Hong, JP; Kim, MS; Park, S; Yi, KK | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; de la Foz, VO; Martinez-Garcia, O; Mata, I; Pérez-Iglesias, R; Suarez-Pinilla, P; Valdizan, EM | 1 |
| Bobes García, J; de la Gándara Martín, JJ; Gutiérrez Fraile, M | 1 |
| Hugdahl, K; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM; Sinkeviciute, I | 1 |
| Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Amado, JA; Ayesa-Arriola, R; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez García, O; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Connolly, JG; Schneeweiss, MC; Toomey, TJ | 1 |
| Álamo, C; Bernardo, M; Bobes, J; Hidalgo, D; Murru, A; Saiz-Ruiz, J; Vieta, E | 1 |
| Brugnoli, R; Carlino, N; D'Andreagiovanni, M; De Giorgi, R; Del Casale, A; Giardini, M; Girardi, P; Kotzalidis, GD; Rapinesi, C; Sacco, M | 1 |
| Das, P | 1 |
| Alonso-Martín, C; Arias-Loste, MT; Crespo, J; Crespo-Facorro, B; Fábrega, E; Martínez-García, O; Morlán-Coarasa, MJ; Ortiz-García de la Foz, V; Romero-Gómez, M | 1 |
| Cross, ES; Davies, W; Guerrero, S; Humby, T; Messer, L | 1 |
| Bai, YH; Cai, M; Chen, YC; Guo, L; McAlonan, GM; Tan, QR; Wang, HH; Wang, HN; Wang, Y; Wu, WJ; Zhang, RG; Zhang, YH; Zhang, ZJ | 1 |
| Amado-Señaris, JA; Ayesa-Arriola, R; Correll, C; Crespo-Facorro, B; Labad, J; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Teresa Garcia-Unzueta, M; Valdizan, EM | 1 |
| Sikich, L | 1 |
| Montejo, AL; Rico-Villademoros, F | 1 |
| DelBello, MP; Ice, K; Keller, D; Miceli, J; Versavel, M | 1 |
| Dietmaier, O; Gansmüller, R; Gründer, G; Hiemke, C; Leiblein, T; Vogel, F; Wassmuth, H | 1 |
| Loebel, A; O'Gorman, CJ; Simpson, GM; Yang, R | 1 |
| Alderman, JA; Gandelman, K; Glue, P; LaBadie, RR; Lombardo, I; Preskorn, SH; Versavel, M | 1 |
| Díaz-Marsá, M; Rico-Villademoros, F; Sánchez, S | 1 |
| Citrome, L; Glue, P; Karayal, ON; Yang, R | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL | 1 |
| Akkaya, C; Alptekin, K; Brook, S; Danaci, AE; El Tallawy, H; Hafez, J; Karayal, ON; Lowe, W; Tzebelikos, E; Ucok, A | 1 |
| Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ | 1 |
| Citrome, L; Jaffe, A; Levine, J | 2 |
| Christodoulou, C; Douzenis, A; Gournellis, R; Lykouras, LP; Rizos, E | 1 |
| Kaushik, S; Lindenmayer, JP; Maccabee, N | 1 |
| Herman, BK; Lawson, WB; Lazariciu, I; Loebel, A; Malik, M | 1 |
| DelBello, MP; Keller, D; Stewart, M; Versavel, M | 1 |
| Anziano, R; Harrigan, RH; Miceli, JJ; O'Gorman, C; Shiovitz, T; Tensfeldt, TG | 1 |
| Barth, KS; Garner, A; Phan, SV; Snarr, BS; VandenBerg, AM | 1 |
| Johnsen, E; Jørgensen, HA; Kroken, RA; Wentzel-Larsen, T | 1 |
| Anziano, RJ; Harrigan, RH; Miceli, JJ; O'Gorman, C; Shiovitz, T; Tensfeldt, TG | 1 |
| Elsom, SJ; Gurvich, C; Kulkarni, J; McCauley-Elsom, K | 1 |
| Lincoln, J; Preskorn, SH; Stewart, ME | 1 |
| Cucchiaro, J; Harvey, PD; Keefe, RS; Loebel, A; Ogasa, M | 1 |
| Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M | 1 |
| Bachinsky, M; Cavus, I; Chappell, P; Glue, P; Karayal, ON; Kolluri, S; Stewart, M | 1 |
| Dadić-Hero, E; Grahovac, T; Ružić, K; Sabljić, V; Sepić-Grahovac, D | 1 |
| Baldaçara, L; Cordeiro, DC; Jackoswski, AP; Sanches, M | 1 |
| Ayyanar, S; Kattimani, S; Menon, V | 1 |
| Bitter, I; Czobor, P; Derks, EM; Fleischhacker, WW; Kahn, RS; Libiger, J; Volavka, J | 1 |
| Johnsen, E; Jørgensen, HA; Kjelby, E; Kroken, RA; Løberg, EM | 1 |
| Cucchiaro, J; Loebel, A; Ogasa, M; Potkin, SG | 1 |
| Jakovljevic, M; Mihaljevic-Peles, A; Muck-Seler, D; Mustapic, M; Nedic, G; Nikolac, M; Pivac, N; Sagud, M; Vuksan Cusa, B | 1 |
| Létourneau, G; Moteshafi, H; Potvin, S; Stikarovska, I; Stip, E; Tourjman, V; Zhornitsky, S | 1 |
| Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I | 1 |
| Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
| Li, YM; Ou, JJ; Wu, RR; Zhao, JP | 1 |
| Chung, YC; Huang, GB; Kim, MG; Lee, KH; Park, TW; Yang, JC; Zhao, T | 1 |
| Bitter, I; Bucci, P; Fleischhacker, WW; Galderisi, S; Kahn, RS; Libiger, J; Mucci, A | 1 |
| Kolluri, S; Newcomer, JW; Pappadopulos, E | 1 |
| Alvarez, E; Arranz, B; Corripio, I; Dueñas, R; Perez, V; Ramirez, N; Safont, G; San, L | 1 |
| Adams, CE; Jones, H; Powney, MJ | 1 |
| Akintola, M; Messerschmidt, C; Morewitz, J; Spiegel, DR | 1 |
| Gunasekara, NS; Keating, GM; Spencer, CM | 2 |
| Boeker, T | 1 |
| McNeely, MJ; Yang, SH | 1 |
| Daniel, DG | 1 |
| Escalona, PR; Lu, BY; Lundgren, R; Roberts, BB | 1 |
| Danileviciūte, V | 1 |
| Kaye, NS | 2 |
| Harvey, PD; Romano, S; Siu, CO | 1 |
| Daniel, DG; Romano, SJ; Simpson, G; Weiden, PJ | 1 |
| Brieger, P | 1 |
| Berardi, D; De Ronchi, D; Lorenzi, C; Serretti, A | 1 |
| Lublin, HK | 1 |
| Jaffe, R; Leavitt, R; Wind, T | 1 |
| Kapur, S; Mamo, D; Mann, S; Papatheodorou, G; Remington, G; Shammi, CM; Therrien, F | 1 |
| McDougle, CJ; Meighen, KG; Shelton, HM | 1 |
| Davids, E; Gastpar, M; Hartwig, U | 1 |
| Ravasia, S; Swensen, E | 1 |
| Hasan, RA; Leibold, J; Patel, V | 1 |
| Glick, ID; Romano, SJ; Simpson, GM; Siu, CO; Weiden, PJ | 1 |
| Finkel, S | 1 |
| Katz, IR | 1 |
| Finzel, M; Fric, M; Laux, G | 1 |
| Blair, J; Martin, A; Scahill, L; State, M | 1 |
| Aguilar, Y; Alvarez, E; Carrió, I; Catafau, AM; Corripio, I; Mena, E; Perez, V; Puigdemont, D | 1 |
| Addington, DE; Benattia, I; Dineen, M; Pantelis, C; Romano, SJ | 1 |
| Staller, JA | 1 |
| Korchounov, A; Oechsner, M | 1 |
| Cole, SA; Jyringi, D; Sablosky, M; Saleem, R; Sedler, M; Shea, WP; Smith, A | 1 |
| Murray, S; Pigott, T; Romano, SJ; Simpson, GM; Siu, CO; Weiden, P | 1 |
| Lin, CL; Luu, SU; Mao, WC; Shiah, IS | 1 |
| Baser, O; Engelhart, L; Finkel, S; Greenspan, A; Kozma, C; Long, S; Mahmoud, R | 1 |
| Allen, MH; Battaglia, J; Citrome, L; Fishkind, A; Francis, A; Herr, DL; Hughes, D; Martel, M; Preval, H; Ross, R; Zimbroff, DL | 1 |
| Mendhekar, DN | 1 |
| Howland, RH | 1 |
| Bond, LC; Borovicka, MC; Gaughan, KM | 1 |
| Hwang, J; Kaufman, KR; Mohebati, A; Olsavsky, A; Stern, L | 1 |
| Daniel, DG; Harvey, PD; Kilts, CD; Lieberman, JA; Nemeroff, CB; Newcomer, JW; Schatzberg, AF; Weiden, PJ | 1 |
| Correll, CU | 1 |
| Bowie, CR; Harvey, PD; Loebel, A | 1 |
| Kostulski, A; Rabe-Jabłońska, J; Wyszogrodzka-Kucharska, A | 1 |
| Adams, DH; Ascher-Svanum, H; Edwards, SB; Kinon, BJ; Lipkovich, I; Siris, SG | 1 |
| Brook, S; Citrome, L; Czobor, P; Loebel, A; Mandel, FS; Volavka, J | 1 |
| Chappell, P; Loebel, A; Miceli, J; Siu, C | 1 |
| Alvarez, E; Barrachina, J; Campins, MJ; Madre, M; Pascual, JC; Pérez, V; Soler, J | 1 |
| Barak, Y; Baruch, Y; Mazeh, D; Plopski, I | 1 |
| Scott, LJ; Swainston Harrison, T | 1 |
| Domin, S; Kasper, S; Kudla, D; Lambert, M; Naber, D | 1 |
| De Oliveira, IR; Juruena, MF | 1 |
| Duggal, HS | 1 |
| Certa, K; Chism, LM; Mago, R; Pinninti, NR | 1 |
| Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D | 1 |
| Agid, O; Kapur, S; Loebel, A; Siu, C; Warrington, L | 1 |
| Davidson, M; Levy, A; Weizer, M | 1 |
| Goff, DC; Herz, L; Kletti, N; Ko, GN; Lapierre, K; Law, CG; Posever, T; Simmons, J; Wilner, KD | 1 |
| Buffenstein, A; Feighner, J; Ferguson, J; Harrigan, EP; Jaffe, W; Keck, P; Morrissey, MR | 1 |
| Kane, JM | 1 |
| Daniel, DG; Harrigan, EP; Lakshminarayanan, M; Potkin, SG; Reeves, KR; Zimbroff, DL | 1 |
| Allison, DB; Cappelleri, JC; Chandler, LP; Heo, M; Infante, MC; Mentore, JL; Weiden, PJ | 1 |
| Bayle, FJ; Ghaoui, S; Olie, JP | 1 |
| Bagnall, A; Kleijnen, J; Leitner, ML; Lewis, RA | 1 |
| Bagnall, A; Leitner, ML; Lewis, RA | 1 |
| Copeland, LF; Daniel, DG | 1 |
| Harrigan, EP; Keck, PE; Reeves, KR | 1 |
| Brook, S; Gunn, KP; Lucey, JV | 1 |
| Harrigan, EP; Lesem, MD; Reeves, KR; Swift, RH; Zajecka, JM | 1 |
| Cañas, F | 1 |
| Casey, DE; Zorn, SH | 1 |
| Daniel, DG; Harrigan, EP; Potkin, SG; Reeves, KR; Swift, RH | 1 |
| Carnahan, RM; Lund, BC; Perry, PJ | 1 |
| Fayek, M; Kingsbury, SJ; Simpson, GM; Trufasiu, D; Zada, J | 1 |
| Green, B | 1 |
| Goodnick, PJ | 1 |
| Gutierrez, MA; Lee, V; Stimmel, GL | 1 |
| Crismon, L; Dorson, PG; Patel, NC; Sierk, P | 1 |
33 review(s) available for ziprasidone and Psychotic Disorders
| Article | Year |
|---|---|
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parkinson Disease; Piperazines; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Urea | 2017 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Antipsychotic switching in schizoaffective disorder: A systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Drug Substitution; Humans; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Risperidone; Thiazoles | 2016 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Antipsychotics in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes, Gestational; Dibenzothiazepines; Female; Humans; Infant, Newborn; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2010 |
Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile.
Topics: Antipsychotic Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Evidence-Based Medicine; Food-Drug Interactions; Humans; Patient Selection; Piperazines; Psychotic Disorders; Receptors, Dopamine D2; Risk Assessment; Thiazoles; Treatment Outcome | 2011 |
Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Body Mass Index; Body Weight; Clinical Trials as Topic; Drug Industry; Fasting; Humans; Lipids; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Time Factors | 2012 |
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Clopenthixol; Dystonia; Haloperidol; Humans; Lorazepam; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Sleep; Thiazoles | 2012 |
Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Humans; Piperazines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2002 |
Recent developments in pharmacotherapy for the acutely psychotic patient.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Pirenzepine; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2002 |
[Schizoaffective disorder: clinical symptoms and present-day approach to treatment].
Topics: Adolescent; Amisulpride; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Child; Diagnosis, Differential; Dibenzothiazepines; Dogs; Female; Humans; Imidazoles; Indoles; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Olanzapine; Piperazines; Pirenzepine; Placebos; Prognosis; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Sulpiride; Thiazoles; Time Factors | 2002 |
New antipsychotics and schizophrenia: a review on efficacy and side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cognition; Dibenzothiazepines; Drug Interactions; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
[Ziprasidone. A new second-generation antipsychotic agent].
Topics: Administration, Oral; Antipsychotic Agents; Dopamine Antagonists; Humans; Injections, Intramuscular; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin Antagonists; Thiazoles | 2004 |
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Serotonin Antagonists; Thiazoles; Treatment Outcome; United States | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2004 |
Best clinical practice with ziprasidone IM: update after 2 years of experience.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Critical Care; Emergency Medical Services; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Severity of Illness Index; Thiazoles | 2005 |
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles; Weight Gain | 2005 |
Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
Topics: Antipsychotic Agents; Area Under Curve; Humans; Injections, Intramuscular; Long QT Syndrome; Piperazines; Psychotic Disorders; Schizophrenia; Tablets; Thiazoles; Treatment Outcome | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
[New antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Clinical Trials as Topic; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Pramipexole; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles | 1997 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Indoles; Male; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Risk Assessment; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 1999 |
Antipsychotic-induced weight gain: a comprehensive research synthesis.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Confidence Intervals; Drug Administration Schedule; Humans; Molindone; Piperazines; Placebos; Psychotic Disorders; Research Design; Thiazoles; Treatment Outcome; Weight Gain | 1999 |
[New antipsychotic agents].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Sulpiride; Thiazoles | 1999 |
Ziprasidone for schizophrenia and severe mental illness.
Topics: Antipsychotic Agents; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2000 |
Ziprasidone for schizophrenia and severe mental illness.
Topics: Antipsychotic Agents; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2000 |
Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Thiazoles | 2000 |
The pharmacology of weight gain with antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanzapine; Piperazines; Pirenzepine; Psychotic Disorders; Quetiapine Fumarate; Rats; Receptors, Neurotransmitter; Schizophrenia; Thiazoles; Weight Gain | 2001 |
Ziprasidone, a new atypical antipsychotic drug.
Topics: Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactions; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Tourette Syndrome | 2001 |
Focus on ziprasidone.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dopamine Antagonists; Humans; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2001 |
Ziprasidone: profile on safety.
Topics: Antipsychotic Agents; Blood Glucose; Electrocardiography; Humans; Lipids; Piperazines; Prolactin; Psychotic Disorders; Thiazoles; Weight Gain | 2001 |
Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactions; Drug Overdose; Humans; Injections, Intramuscular; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Tourette Syndrome | 2002 |
Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
Topics: Administration, Oral; Antipsychotic Agents; Clinical Trials as Topic; Drug Interactions; Humans; Injections, Intramuscular; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome | 2002 |
66 trial(s) available for ziprasidone and Psychotic Disorders
| Article | Year |
|---|---|
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2020 |
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Symptom Flare Up; Thiazoles; Time Factors | 2020 |
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Energy Metabolism; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Weight Gain; Young Adult | 2020 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2017 |
Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Triglycerides; Young Adult | 2018 |
Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Humans; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Young Adult | 2018 |
Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Outcome Assessment, Health Care; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Retrospective Studies; Thiazoles; Time Factors; Young Adult | 2013 |
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Appetite; Benzodiazepines; Body Composition; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Energy Metabolism; Female; Humans; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2013 |
Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Female; Humans; Male; Patient Dropouts; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Hallucinations; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2013 |
Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sex Factors; Thiazoles; Weight Gain | 2014 |
Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Incidence; Male; Metabolic Diseases; Middle Aged; Non-alcoholic Fatty Liver Disease; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2016 |
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Single-Blind Method; Thiazoles; Treatment Outcome; Weight Gain | 2017 |
Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Cohort Studies; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Sex Characteristics; Thiazoles; Time Factors; Young Adult | 2017 |
Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Male; Piperazines; Prospective Studies; Psychotic Disorders; Schizophrenia; Sexual Dysfunction, Physiological; Thiazoles | 2008 |
Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Male; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Severity of Illness Index; Thiazoles | 2008 |
Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2008 |
The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.
Topics: Adult; Antipsychotic Agents; Biological Availability; Bipolar Disorder; Cross-Over Studies; Dietary Fats; Drug Administration Schedule; Energy Intake; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Young Adult | 2009 |
Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administration Schedule; Female; Hospitalization; Humans; In Vitro Techniques; Length of Stay; Piperazines; Prospective Studies; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2009 |
Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles | 2009 |
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles | 2009 |
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Basal Ganglia Diseases; Benzodiazepines; Biperiden; Blood Glucose; Body Weight; Cholesterol; Chronic Disease; Electrocardiography; Female; Humans; Male; Muscarinic Antagonists; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychometrics; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Triglycerides; Young Adult | 2011 |
Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Black People; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Health Status; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quality of Life; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Social Behavior; Thiazoles; Treatment Outcome | 2009 |
Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles | 2010 |
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Galactorrhea; Hospitalization; Humans; Length of Stay; Male; Olanzapine; Patient Readmission; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Severity of Illness Index; Thiazoles; Treatment Outcome | 2010 |
Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Blood Pressure; Dose-Response Relationship, Drug; Electrocardiography; Female; Haloperidol; Heart Rate; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Single-Blind Method; Thiazoles; Young Adult | 2010 |
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interview, Psychological; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Young Adult | 2011 |
Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Cholesterol; Cognition; Dibenzothiazepines; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; Young Adult | 2011 |
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Haloperidol; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Male; Midazolam; Olanzapine; Piperazines; Promethazine; Psychomotor Agitation; Psychotic Disorders; Thiazoles; Tranquilizing Agents | 2011 |
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Haloperidol; Hostility; Humans; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome | 2011 |
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Benzodiazepines; Depression; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles | 2011 |
Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Body Weight; Cholesterol; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2011 |
The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients.
Topics: Antipsychotic Agents; Blood Platelets; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin; Serotonin Antagonists; Thiazoles; Time Factors | 2012 |
Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comparative Effectiveness Research; Dose-Response Relationship, Drug; Drug Monitoring; Episode of Care; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors; Treatment Outcome; Weight Gain | 2012 |
Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Patient Dropouts; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Thiazoles | 2012 |
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Psychomotor Disorders; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles; Treatment Outcome; Young Adult | 2013 |
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Ziprasidone augmentation of clozapine in 11 patients.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain | 2003 |
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition; Double-Blind Method; Female; Hospitalization; Humans; Male; Memory; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles | 2004 |
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Female; Health Status Indicators; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Withholding Treatment | 2003 |
A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Topics: Adult; Antipsychotic Agents; Brain; Corpus Striatum; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychotic Disorders; Pyrimidinones; Raclopride; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Schizophrenia; Thiazoles; Tomography, Emission-Computed | 2004 |
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lorazepam; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain | 2004 |
[QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey].
Topics: Antipsychotic Agents; Electrocardiography; Germany; Hospitalization; Hospitals, Psychiatric; Humans; Long QT Syndrome; Piperazines; Prospective Studies; Psychotic Disorders; Risk Assessment; Thiazoles; Torsades de Pointes | 2004 |
Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study.
Topics: Adolescent; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Obsessive-Compulsive Disorder; Piperazines; Prospective Studies; Psychotic Disorders; Thiazoles; Tourette Syndrome | 2005 |
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzamides; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Neostriatum; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Single-Blind Method; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Failure | 2005 |
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Sexual Dysfunctions, Psychological; Sleep Initiation and Maintenance Disorders; Thiazoles; Treatment Outcome | 2004 |
Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Electrocardiography; Emergency Medical Services; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2005 |
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome; Weight Gain | 2005 |
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Patient Admission; Piperazines; Psychometrics; Psychotic Disorders; Schizophrenia; Thiazoles | 2006 |
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Depression; Glycated Hemoglobin; Humans; Olanzapine; Patient Dropouts; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Triglycerides; United States; Weight Gain | 2006 |
Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; Hostility; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2006 |
Intramuscular ziprasidone treatment of acute psychotic agitation in elderly patients with schizophrenia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antipsychotic Agents; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Schizophrenia; Thiazoles | 2006 |
Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Thiazoles; Time Factors; Treatment Outcome | 2008 |
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 1998 |
Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles | 1998 |
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Thiazoles | 1999 |
Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Movement Disorders; Piperazines; Psychotic Disorders; Thiazoles; Treatment Outcome | 2001 |
Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Administration Schedule; Female; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychotic Disorders; Severity of Illness Index; Thiazoles; Treatment Outcome | 2000 |
Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients.
Topics: Antipsychotic Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Thiazoles; Treatment Outcome | 2001 |
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2001 |
The apparent effects of ziprasidone on plasma lipids and glucose.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lipids; Male; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Schizophrenia; Thiazoles; Triglycerides | 2001 |
49 other study(ies) available for ziprasidone and Psychotic Disorders
| Article | Year |
|---|---|
Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.
Topics: Animals; Behavior, Animal; Brain; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Locomotion; Molecular Structure; Psychotic Disorders; Rats; Serotonin; Serotonin Receptor Agonists; Structure-Activity Relationship | 2012 |
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.
Topics: Adult; Benzodiazepines; Female; Humans; Male; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Substance-Related Disorders; Thiazoles | 2021 |
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes, Gestational; Female; Humans; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Thiazoles; Young Adult | 2018 |
Switching to ziprasidone in the clinical practice setting: an open-label study.
Topics: Adult; Antipsychotic Agents; Body Weight; Brief Psychiatric Rating Scale; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychometrics; Psychotic Disorders; Quality of Life; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome | 2013 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Blood Glucose; Child; Child, Preschool; Cohort Studies; Conduct Disorder; Databases, Factual; Depressive Disorder; Diabetes Mellitus; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hyperkinesis; Male; Mass Screening; Mental Disorders; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risperidone; Thiazoles | 2015 |
Effectiveness of switching from oral ziprasidone to risperidone in a patient with comorbid autistic disorder, profound intellectual disability, Gilbert syndrome, and exacerbation of psychosis.
Topics: Adult; Antipsychotic Agents; Autistic Disorder; Comorbidity; Gilbert Disease; Humans; Intellectual Disability; Male; Piperazines; Psychotic Disorders; Risperidone; Thiazoles | 2016 |
A Case of Sleepwalking With Sleep-Related Eating Associated With Ziprasidone Therapy in a Patient With Schizoaffective Disorder.
Topics: Adult; Antipsychotic Agents; Feeding and Eating Disorders; Humans; Male; Parasomnias; Piperazines; Psychotic Disorders; Somnambulism; Thiazoles | 2016 |
A pharmacological mouse model suggests a novel risk pathway for postpartum psychosis.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Coumarins; Disease Models, Animal; Female; Gene Expression; Mice; Mice, Inbred C57BL; Piperazines; Psychotic Disorders; Puerperal Disorders; Steryl-Sulfatase; Sulfonamides; Thiazoles | 2016 |
The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Mood Disorders; Piperazines; Psychotic Disorders; Retrospective Studies; Severity of Illness Index; Thiazoles; Treatment Outcome | 2009 |
How dosing of ziprasidone in a state hospital system differs from product labeling.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Utilization; Female; Hospitalization; Hospitals, Psychiatric; Hospitals, State; Humans; Male; Piperazines; Prescription Drugs; Product Labeling; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Treatment Outcome | 2009 |
Tardive dyskinesia in a patient treated with quetiapine.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride; Thiazoles | 2009 |
Activation induced by high-dose ziprasidone: a case report.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Thiazoles | 2009 |
Symptomatic bradycardia with oral aripiprazole and oral ziprasidone.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Bradycardia; Delusions; Electrocardiography; Female; Humans; Lithium Carbonate; Piperazines; Psychotic Disorders; Quinolones; Thiazoles | 2010 |
How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Biological Availability; Biomedical Research; Bipolar Disorder; Dietary Fats; Dose-Response Relationship, Drug; Drug Evaluation; Drug Monitoring; Drugs, Investigational; Energy Intake; Fasting; Female; Food-Drug Interactions; Humans; Intestinal Absorption; Male; Middle Aged; Piperazines; Postprandial Period; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Weight gain--as possible predictor of metabolic syndrome.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dibenzothiazepines; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Metabolic Syndrome; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Thiazoles; Weight Gain | 2011 |
Ziprasidone induced symptomatic bradycardia: a case report.
Topics: Adult; Antipsychotic Agents; Bradycardia; Humans; Male; Piperazines; Psychotic Disorders; Thiazoles | 2011 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome | 2011 |
A case of recurrent psychosis during sickle cell disease crisis treated successfully with ziprasidone.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antipsychotic Agents; Blood Transfusion; Diagnosis, Differential; Fluid Therapy; Hospitalization; Humans; Male; Pain; Pain Management; Piperazines; Psychotic Disorders; Recurrence; Thiazoles | 2013 |
Ziprasidone and migraine headache.
Topics: Adult; Antipsychotic Agents; Drug Interactions; Female; Humans; Migraine Disorders; Photophobia; Piperazines; Psychotic Disorders; Pyrantel Pamoate; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles; Trismus | 2002 |
Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone.
Topics: Antipsychotic Agents; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Fever; Humans; Hyperglycemia; Middle Aged; Muscle Rigidity; Neuroleptic Malignant Syndrome; Pancreatitis; Piperazines; Psychotic Disorders; Rhabdomyolysis; Thiazoles | 2002 |
A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Humans; Male; Piperazines; Psychotic Disorders; Serotonin; Thiazoles | 2002 |
Psychic akathisia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Humans; Piperazines; Psychotic Disorders; Thiazoles | 2003 |
Hypomanic episodes after receiving ziprasidone: an unintended "on-off-on" course of treatment.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Drug Administration Schedule; Humans; Male; Piperazines; Psychotic Disorders; Thiazoles | 2004 |
QTc prolongation in multiple drug overdose.
Topics: Adult; Bupropion; Drug Overdose; Fluoxetine; Humans; Long QT Syndrome; Male; Piperazines; Psychotic Disorders; Thiazoles; Valproic Acid | 2004 |
Ziprasidone treatment of two adolescents with psychosis.
Topics: Adolescent; Female; Humans; Male; Piperazines; Psychotic Disorders; Thiazoles | 2004 |
Antipsychotic treatment of psychosis associated with multiple sclerosis.
Topics: Antipsychotic Agents; Female; Humans; Middle Aged; Multiple Sclerosis; Piperazines; Psychotic Disorders; Schizophrenic Psychology; Thiazoles | 2004 |
Ziprasidone-induced lupus erythematosus.
Topics: Depressive Disorder, Major; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Piperazines; Psychotic Disorders; Serotonin Antagonists; Thiazoles | 2004 |
Neuroleptic malignant syndrome associated with ziprasidone in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Thiazoles | 2004 |
Intramuscular ziprasidone in youth: a retrospective chart review.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Retrospective Studies; Thiazoles; Treatment Outcome | 2004 |
Ziprasidone for agitation or psychosis in dementia: four cases.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Psychomotor Agitation; Psychotic Disorders; Retrospective Studies; Thiazoles | 2005 |
Ziprasidone in the treatment of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperazines; Psychotic Disorders; Taiwan; Thiazoles; Treatment Outcome | 2006 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort Studies; Dementia; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Haloperidol; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Patient Admission; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risk Factors; Risperidone; Thiazoles | 2005 |
Ziprasidone-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Psychotic Disorders; Thiazoles | 2005 |
Atypical antipsychotics: special formulations for acute agitation.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Risperidone; Thiazoles | 2005 |
Ziprasidone- and lithium-induced neuroleptic malignant syndrome.
Topics: Antipsychotic Agents; Humans; Hypotension; Lithium; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Thiazoles | 2006 |
Ziprasidone-induced priapism requiring surgical treatment.
Topics: Adult; Bipolar Disorder; Erectile Dysfunction; Humans; Male; Piperazines; Priapism; Psychotic Disorders; Thiazoles | 2006 |
From clinical research to clinical practice: a 4-year review of ziprasidone.
Topics: Antipsychotic Agents; Controlled Clinical Trials as Topic; Dopamine Antagonists; Humans; Mood Disorders; Piperazines; Psychotic Disorders; Schizophrenia; Serotonin Antagonists; Thiazoles; Treatment Outcome | 2005 |
Real-life switching strategies with second-generation antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Cohort Studies; Dibenzothiazepines; Drug Administration Schedule; Drug Resistance; Humans; Mental Disorders; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Selection Bias; Thiazoles; Treatment Outcome | 2006 |
Electrocardiographic changes with ziprasidone.
Topics: Adolescent; Antipsychotic Agents; Child; Data Interpretation, Statistical; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Piperazines; Psychotic Disorders; Research Design; Selection Bias; Thiazoles; Tourette Syndrome | 2006 |
Injectable atypical antipsychotics for agitation in borderline personality disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Disorder; Comorbidity; Emergency Services, Psychiatric; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Schizophrenia; Thiazoles; Treatment Outcome | 2006 |
Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: results of a multi-centre observational trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Austria; Blood Glucose; Body Weight; Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Lipids; Male; Middle Aged; Patient Dropouts; Piperazines; Product Surveillance, Postmarketing; Prospective Studies; Psychotic Disorders; Quality of Life; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Datapoints: The ups and downs of dosing second-generation antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles | 2007 |
Acute pisa syndrome and pharnygolaryngeal dystonia due to ziprasidone.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Male; Pharyngeal Diseases; Piperazines; Psychotic Disorders; Thiazoles | 2008 |
Urinary retention associated with ziprasidone: a case report.
Topics: Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders; Efferent Pathways; Female; Humans; Middle Aged; Muscle Contraction; Muscle, Smooth; Piperazines; Psychotic Disorders; Raphe Nuclei; Thiazoles; Urinary Bladder; Urinary Retention | 2008 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles | 2008 |
Sustaining short-term gains for future progress.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Humans; Injections, Intramuscular; Piperazines; Psychotic Disorders; Thiazoles | 2001 |
Experience with ziprasidone.
Topics: Adolescent; Antipsychotic Agents; Contraindications; Depressive Disorder, Major; Drug Evaluation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Piperazines; Psychotic Disorders; Thiazoles | 2002 |